IP Library Granted Patent US 7,943,762
Granted Patent B2
US 7,943,762 · App. 11/801,885 · Granted May 17, 2011

Oligonucleotide analogs having cationic intersubunit linkages

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,762
App. No.
11/801,885
Granted
May 17, 2011
Kind
B2
Abstract

Morpholino oligomers containing both uncharged and cationic intersubunit linkages are provided. The oligomers are oligonucleotide analogs containing predetermined sequences of base-pairing moieties. The presence of the cationic intersubunit linkages in the oligomers, typically at a level of about 10-50% of total linkages, provides enhanced antisense activity, in various antisense applications, relative to the corresponding uncharged oligomers. Also provided are such oligomers conjugated to peptide transporter moieties, where the transporters are preferably composed of arginine subunits, or arginine dimers, alternating with neutral amino acid subunits.

Claims (28)

1. An oligomer comprising a sequence of morpholino subunits, each morpholino subunit comprising a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein the morpholino subunits are each joined by a phosphorus-containing intersubunit linkage having the structure:

wherein:

W is S or O;

X is NR 1 R 2 or OR 6 ;

Y is O or NR 7 ;

and the intersubunit linkage is, at each occurrence, independently:

linkage (a), where each of R 1 , R 2 , R 6 and R 7 is independently hydrogen or lower alkyl; or

linkage (b1), where X is NR 1 R 2 , Y is O and NR 1 R 2 is a piperazino group, such that R 1 R 2 is —CHRCHRN(R 3 )(R 4 )CHRCHR—, wherein:

each R is, at each occurrence, independently H or CH 3 ;

R 4 is H, CH 3 or an electron pair; and

R 3 is H, lower alkyl, —C(═NH)NH 2 , —Z-L-NHC(═NH)NH 2 or —[C(O)CHR′NH] m H, where Z is carbonyl (C(O)) or a direct bond, L is an optional linker up to 18 atoms in length comprising alkyl, alkoxy or alkylamino groups, or combinations thereof, R′ is a side chain of a naturally occurring amino acid or a one- or two-carbon homolog thereof, and m is 1 to 6;

and at least one intersubunit linkage is linkage (b1).

2. The oligomer of claim 1 , wherein each of the morpholino subunits have the structure (i):

where each Pi is, at each occurrence, independently a base-pairing moiety, and the intersubunit linkage connects the nitrogen atom of (i) to the 5′ carbon of an adjacent morpholino subunit.

3. The oligomer of claim 1 , wherein each linkage (b1) in the oligomer has the same W, X and Y groups.

4. The oligomer of claim 1 , wherein 5% to 50% of the intersubunit linkages in the oligomer are linkage (b1).

5. The oligomer of claim 4 , wherein 10% to 35% of the intersubunit linkages in the oligomer are linkage (b1).

6. The oligomer of claim 1 , wherein for each occurrence of linkage (a), X is NR 1 R 2 , and each of R 1 and R 2 is methyl.

7. The oligomer of claim 1 , wherein the oligomer comprises at least two consecutive intersubunit linkages of linkage (a).

8. The oligomer of claim 1 having a length of 10 to 40 subunits.

9. The oligomer of claim 1 having a length of 15 to 25 subunits.

10. The oligomer of claim 1 , wherein each R is H, R 4 is H, CH 3 or an electron pair, and R 3 is H, CH 3 , —C(═NH)NH 2 or —C(O)-L-NHC(═NH)NH 2 .

11. The oligomer of claim 1 , wherein each R is H, R 3 is H or CH 3 and R 4 is an electron pair, H or CH 3 .

12. The oligomer of claim 11 , wherein each of R 3 and R 4 is H, and linkage (b1) has the following structure (iv):

13. The oligomer of claim 1 , wherein each of W and Y are O.

14. The oligomer of claim 11 , wherein R 3 is H, R 4 is an electron pair and linkage (b1) has the following structure (v):

15. The oligomer of claim 14 , wherein each of W and Y are O.

16. The oligomer of claim 1 , wherein Z is a direct bond and L has the structure —(CH 2 ) n — where n is 1-12.

Assignments (3)
SECURITY INTEREST Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2009
From: CAI, BAO ZHONG
To: AVI BIOPHARMA, INC.
Reel/Frame 022794/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2007
From: WELLER, DWIGHT D., MR.; HASSINGER, JED N., MR.
To: AVI BIOPHARMA, INC.
Reel/Frame 020020/0937 →